Barclays lowered the firm’s price target on Amdocs to $105 from $115 and keeps an Overweight rating on the shares. The company’s fiscal 2024 guidance missed both estimates with Amdocs pointing to a slowdown in legacy investments, the analyst tells investors in a research note. The firm sees the company as well positioned to capitalize on new domain growth, but says this might take longer than anticipated given the macro headwinds.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DOX:
- Amdocs Limited (DOX) Q4 Earnings Cheat Sheet
- etisalat by e& selects Amdocs to transform in-store retail experience
- Amdocs, Bharti Airtel collaborate for digital transformation
- Amdocs says Israel operations ‘continue without material interruption’
- Amdocs enables migration of classic applications to Azure, OCI